WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsNeuropace Inc (NPCE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 20978% more annual revenue ($20.98B vs $99.53M). GEHC leads profitability with a 9.1% profit margin vs -21.7%. GEHC earns a higher WallStSmart Score of 57/100 (C).

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

NPCE

Avoid

21

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: -5.89
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GEHC.

NPCESignificantly Overvalued (-24.3%)

Margin of Safety

-24.3%

Fair Value

$11.71

Current Price

$16.32

$4.61 premium

UndervaluedFair: $11.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

NPCE0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

NPCE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$536.64M3/10

Smaller company, higher risk/reward

Price/BookValuation
38.0x2/10

Trading at 38.0x book value

Return on EquityProfitability
-149.2%2/10

ROE of -149.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bull Case : NPCE

NPCE has a balanced fundamental profile.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : NPCE

The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 4.87 is elevated, increasing financial risk.

Key Dynamics to Monitor

GEHC profiles as a value stock while NPCE is a turnaround play — different risk/reward profiles.

NPCE carries more volatility with a beta of 1.88 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Neuropace Inc

HEALTHCARE · MEDICAL DEVICES · USA

NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.

Want to dig deeper into these stocks?